{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diverticular-disease/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"231102c0-511c-5785-ac06-8720d28571cb","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 221028e3-bddb-4bc3-bee1-e223736dbeab --><h2>Metronidazole</h2><!-- end field 221028e3-bddb-4bc3-bee1-e223736dbeab -->","summary":"","htmlStringContent":"<!-- begin item 18012f56-f94d-4037-863c-e8779b1a9023 --><!-- end item 18012f56-f94d-4037-863c-e8779b1a9023 -->","topic":{"id":"94c44346-c791-5b97-9e45-bacb8fe90589","topicId":"eee234d5-c667-4944-95d2-a45f5e032286","topicName":"Diverticular disease","slug":"diverticular-disease","lastRevised":"Last revised in January 2021","chapters":[{"id":"5bcd7ed5-7ab4-57a1-a517-99ee8bb7b2d5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5abc06b8-fef4-5d67-81ce-ee1c71284864","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"71ba91f6-898b-5f69-bd52-93f3b1892ad6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7460514b-3977-52be-9e12-06486604b194","slug":"changes","fullItemName":"Changes"},{"id":"909831b0-6f3c-5e85-8263-a5e1785b8a49","slug":"update","fullItemName":"Update"}]},{"id":"fcd203c7-5d1a-5fcc-ab90-5286ab76bd2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2cbe6fe5-f942-566e-9136-915145ba8517","slug":"goals","fullItemName":"Goals"},{"id":"ffcabc25-6966-526d-8382-a5fcf56185ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"dc0b24e2-e0db-5829-baf5-a7aae6d5ab67","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b5dcfe41-ec7c-5a9f-bc96-229f8b818a77","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d9311147-ff58-5778-bb86-c0249937ef45","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b76632c-4924-5c26-99ab-549b62bb2f73","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"435ea69d-fb08-554b-b803-cc64d393575b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"12666ff2-dbf6-51be-b83a-78c0d4aa12e3","slug":"definition","fullItemName":"Definition"},{"id":"3a4412ce-ae17-58e7-8460-9ab759755b96","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"11908cbc-fb2b-525e-9bed-e9da60b6ad8a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2efdd449-ac81-531a-9514-72e57632cf72","slug":"complications","fullItemName":"Complications"},{"id":"2bb98737-1604-5f47-8f96-27003159f003","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"b9740a9c-8383-57e1-8cc6-7fea164147c7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"411e61cd-aad7-5e40-bf27-38061aae07cb","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"21f90600-3a9d-5e53-92e4-7305f17db5aa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"c90663d3-95e7-5f18-9718-27a43a51abbf","fullItemName":"Management","slug":"management","subChapters":[{"id":"43142f56-faaf-50dc-a1b7-1d4fb26d1a5e","slug":"diverticulosis","fullItemName":"Scenario: Diverticulosis"},{"id":"a1baccf2-7945-577b-b755-eff86d33201c","slug":"diverticular-disease","fullItemName":"Scenario: Diverticular disease"},{"id":"0c23dfbe-5e71-5eeb-9b03-6b3377f49225","slug":"acute-diverticulitis","fullItemName":"Scenario: Acute diverticulitis"}]},{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2bc84877-2507-5c10-af40-fef065820ce1","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"ba178fdc-1c2f-58e1-aec7-b1f903ed5207","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"524ca556-9a60-542a-9102-901470ef4882","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"463ca371-3542-5765-8350-4a0a640f0cae","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"231102c0-511c-5785-ac06-8720d28571cb","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f2cde7d6-3b3a-5b9f-bf9c-9c7445a1ae6f","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"8b942243-eed9-557a-9678-01f6c77e2b91","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7ccd6405-b8ec-557d-9d70-bce3f43accbd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"544db73d-5bf7-5ac9-81f4-784210ec7343","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f2fb4d8d-7ad7-55ef-837b-a9faa80ba34d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8cbe5c96-baf1-5b25-af5c-6f36a3d9ea3c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7518d3a3-e804-5074-908b-2b9f984cbf60","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e84d6049-8652-59d8-a02d-c49972295f21","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1de75d4a-a4c8-5742-add9-eabcb6711bcb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a47d3fe5-30c0-5b8d-bba4-12dc57a2b458","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3738415d-6a43-495d-bfd8-f0e9bb5a8c82 --><h3>Contraindications and cautions</h3><!-- end field 3738415d-6a43-495d-bfd8-f0e9bb5a8c82 -->","summary":"","htmlStringContent":"<!-- begin item e2ac2136-9a8e-4843-9532-a6a236a5ff00 --><!-- begin field d093aa92-bebe-4231-969a-6f420fd68303 --><ul><li><strong>Do not prescribe metronidazole to a person with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li><li>Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories). For people with Cockayne syndrome specialist advice should therefore be sought before prescribing metronidazole. </li></ul></li><li><strong>Prescribe metronidazole with caution </strong><strong>to people with:</strong><ul><li>Active or chronic severe peripheral and central nervous system disease, as there is a risk of neurological aggravation.</li><li>Severe liver disease or hepatic encephalopathy, due to substantial impairment of metronidazole clearance, which may contribute to symptoms of encephalopathy. Prescribe one-third of the daily dosage once daily.</li><li>Alcohol dependency — there may be a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) if taken with alcohol.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 73, 2017</a>]</p><!-- end field d093aa92-bebe-4231-969a-6f420fd68303 --><!-- end item e2ac2136-9a8e-4843-9532-a6a236a5ff00 -->","subChapters":[]},{"id":"ed47baae-4922-58d7-85ba-8d5eb41dd540","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4c2a269c-cbc2-4e8c-9d3d-7d700e3370a8 --><h3>Adverse effects</h3><!-- end field 4c2a269c-cbc2-4e8c-9d3d-7d700e3370a8 -->","summary":"","htmlStringContent":"<!-- begin item c93b387a-399d-4cf2-83b4-bebe3cac5cc3 --><!-- begin field 3ecc07fd-7ce4-4017-aca8-ed23e037f575 --><p><strong>Adverse effects of metronidazole include:</strong><strong> </strong> </p><ul><li>Gastrointestinal disturbances including nausea and vomiting, anorexia, and very rarely hepatitis, jaundice, or pancreatitis.</li><li>Possible disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) if the person drinks alcohol.</li><li>Taste disturbances, furred tongue, oral mucositis.</li><li>Headache, ataxia.</li><li>Thrombocytopenia, pancytopenia. </li><li>Myalgia, arthralgia.</li><li>Darkening of urine.</li><li>Rash, pruritus, and erythema multiforme.</li><li>Drowsiness, dizziness, confusion, hallucinations, convulsions, or transient visual disorders. Advise the person not to drive or operate machinery if these symptoms occur.</li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 73, 2017</a>]</p><!-- end field 3ecc07fd-7ce4-4017-aca8-ed23e037f575 --><!-- end item c93b387a-399d-4cf2-83b4-bebe3cac5cc3 -->","subChapters":[]},{"id":"fc267643-0565-525f-bf42-801bdd6491fe","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 19ba8488-ad63-4535-9899-a7b300e6de7a --><h3>Drug interactions</h3><!-- end field 19ba8488-ad63-4535-9899-a7b300e6de7a -->","summary":"","htmlStringContent":"<!-- begin item 76b9bde3-f59b-4842-9167-a7b300e6dc96 --><!-- begin field c2ed1328-62fa-45b4-a7e6-a7b300e6de7a --><p><strong>Drug interactions associated with metronidazole include: </strong></p><ul><li><strong>Alcohol </strong>— some people taking metronidazole experience a disulfiram-like reaction with alcohol.<ul><li>Warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst on metronidazole and for at least 48 hours afterwards. </li></ul></li><li><strong>Anticoagulants</strong> — the anticoagulant effects of warfarin can be markedly increased by metronidazole. <ul><li>Monitor the international normalized ratio (INR) and adjust the warfarin dose accordingly. </li></ul></li><li><strong>Ciclosporin</strong> — if co-administration of metronidazole and ciclosporin is necessary, serum ciclosporin levels and serum creatinine should be closely monitored.</li><li><strong>Cimetidine</strong> — metabolism of metronidazole inhibited by cimetidine, resulting in an increased plasma concentration.</li><li><strong>Lithium </strong>— seek specialist advice regarding the use of metronidazole with lithium, as metronidazole increases the risk of lithium toxicity. Lithium dose reduction may be required due to the risk of renal damage with concurrent use. Plasma concentrations of lithium, creatinine, and electrolytes should be monitored if metronidazole and lithium are used simultaneously.</li><li><strong>Phenytoin</strong> — metronidazole possibly inhibits the metabolism of phenytoin, leading to increased plasma concentrations.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 73, 2017</a>]</p><!-- end field c2ed1328-62fa-45b4-a7e6-a7b300e6de7a --><!-- end item 76b9bde3-f59b-4842-9167-a7b300e6dc96 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}